RBC Capital analyst Conor McNamara raised the firm’s price target on Illumina to $303 from $284 and keeps an Outperform rating on the shares after its Q4 results and guidance. The company enters 2023 after a year of declining revenue and profitability and no answer from the FTC on the future of the Grail acquisition, the analyst tells investors in a research note. The firm remains positive on the name however and contends that Illumina’s current stock price over-discounts the likelihood of share erosion from smaller competitors and does not factor in years of R&D spend and product innovation that the company has invested in the next gen sequencing market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ILMN:
- Illumina price target raised to $230 from $210 at BofA
- Illumina price target lowered to $150 from $160 at Barclays
- Illumina sees FY23 adjusted EPS $1.25-$1.50, consensus $1.98
- Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2022
- Illumina reports Q4 adjusted EPS 14c, consensus 10c